Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain

NCT02603705 is registered in ClinicalTrials.gov with Egalet Ltd as lead sponsor.

NCT NCT02603705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02603705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain
Lead sponsor
Egalet Ltd
Phase
Phase 3
Overall status
Completed
Start date
March 7, 2016
Completion date
June 15, 2017
Enrollment
281 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe chronic noncancer pain